Clinical Significance of Molecular Subtypes of Gastrointestinal Tract Adenocarcinoma

Overview

Journal World J Gastrointest Oncol

Publisher Baishideng Publishing Group

Date 2022 Mar 24

PMID 35321271

Authors

Ekaterina Olegovna Ignatova

Evgenii Kozlov

Maxim Ivanov

Vladislav Mileyko

Sofia Menshikova

Henian Sun

Mikhail Fedyanin

Alexey Tryakin

Ivan Stilidi

Affiliations

Soon will be listed here.

Abstract

Adenocarcinomas of the gastrointestinal tract (esophagus, stomach, and colon) represent a heterogeneous group of diseases with distinct etiology, clinical features, treatment approaches, and prognosis. Studies are ongoing to isolate molecular genetic subtypes, perform complete biological characterization of the tumor, determine prognostic groups, and find predictive markers to the effectiveness of therapy. Separate molecular genetic classifications were created for esophageal adenocarcinoma [The Cancer Genome Atlas (TCGA)], stomach cancer (TCGA, Asian Cancer Research Group), and colon cancer (Colorectal Cancer Subtyping Consortium). In 2018, isolation of TCGA molecular genetic subtypes for adenocarcinomas of the gastrointestinal tract (esophagus, stomach, and colon) highlighted the need for further studies and clinical validation of subtyping of gastrointestinal adenocarcinomas. However, this approach has limitations. The aim of our work was to critically analyze integration of molecular genetic subtyping of gastrointestinal adenocarcinomas in clinical practice.

Citing Articles

Research advances in the molecular classification of gastric cancer.

Shi D, Yang Z, Cai Y, Li H, Lin L, Wu D Cell Oncol (Dordr). 2024; 47(5):1523-1536.

PMID: 38717722 PMC: 11466988. DOI: 10.1007/s13402-024-00951-9.

Combined score of Y chromosome loss and T-cell infiltration improves UICC based stratification of esophageal adenocarcinoma.

Raters V, Gebauer F, Loser H, Schroder W, Schlosser H, Fuchs H Front Oncol. 2023; 13:1249172.

PMID: 38045001 PMC: 10693404. DOI: 10.3389/fonc.2023.1249172.

OLIGOMETASTASIS IN GASTRIC CANCER TREATMENT: IS THERE A PLACE FOR THE SURGEON?.

Assumpcao P, Silva J, Calcagno D, Barra W, Ishak G, Kassab P Arq Bras Cir Dig. 2023; 36:e1752.

PMID: 37729281 PMC: 10510098. DOI: 10.1590/0102-672020230034e1752.

A Novel Molecular Analysis Approach in Colorectal Cancer Suggests New Treatment Opportunities.

Lopez-Camacho E, Prado-Vazquez G, Martinez-Perez D, Ferrer-Gomez M, Llorente-Armijo S, Lopez-Vacas R Cancers (Basel). 2023; 15(4).

PMID: 36831448 PMC: 9953902. DOI: 10.3390/cancers15041104.

Putative Clinical Potential of Amplification Assessment by ddPCR in FFPE-DNA and cfDNA of Gastroesophageal Adenocarcinoma Patients.

Boldrin E, Mazza M, Piano M, Alfieri R, Montagner I, Magni G Cancers (Basel). 2022; 14(9).

PMID: 35565309 PMC: 9102116. DOI: 10.3390/cancers14092180.

References

Yun T, Liu Y, Gao D, Linghu E, Brock M, Yin D . Methylation of CHFR sensitizes esophageal squamous cell cancer to docetaxel and paclitaxel. Genes Cancer. 2015; 6(1-2):38-48. PMC: 4362483. DOI: 10.18632/genesandcancer.46. View

Van Cutsem E, Bang Y, Mansoor W, Petty R, Chao Y, Cunningham D . A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. Ann Oncol. 2017; 28(6):1316-1324. DOI: 10.1093/annonc/mdx107. View

Hegi M, Diserens A, Gorlia T, Hamou M, De Tribolet N, Weller M . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003. DOI: 10.1056/NEJMoa043331. View

. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517):202-9. PMC: 4170219. DOI: 10.1038/nature13480. View

Donnem T, Hu J, Ferguson M, Adighibe O, Snell C, Harris A . Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?. Cancer Med. 2013; 2(4):427-36. PMC: 3799277. DOI: 10.1002/cam4.105. View

Lordick F, Kang Y, Chung H, Salman P, Oh S, Bodoky G . Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013; 14(6):490-9. DOI: 10.1016/S1470-2045(13)70102-5. View

Noh S, Park S, Yang H, Chung H, Chung I, Kim S . Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15(12):1389-96. DOI: 10.1016/S1470-2045(14)70473-5. View

Sohn B, Hwang J, Jang H, Lee H, Oh S, Shim J . Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. Clin Cancer Res. 2017; 23(15):4441-4449. PMC: 5785562. DOI: 10.1158/1078-0432.CCR-16-2211. View

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

10.

Kauppila J, Mattsson F, Brusselaers N, Lagergren J . Prognosis of oesophageal adenocarcinoma and squamous cell carcinoma following surgery and no surgery in a nationwide Swedish cohort study. BMJ Open. 2018; 8(5):e021495. PMC: 5950652. DOI: 10.1136/bmjopen-2018-021495. View

11.

Choi Y, Kim H, Shin S, Kim H, Lee J, Yang H . Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study. Ann Surg. 2018; 270(2):309-316. DOI: 10.1097/SLA.0000000000002803. View

12.

Abdel-Latif M, Duggan S, Reynolds J, Kelleher D . Inflammation and esophageal carcinogenesis. Curr Opin Pharmacol. 2009; 9(4):396-404. DOI: 10.1016/j.coph.2009.06.010. View

13.

Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Barber L, Woolston A . CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. J Immunother Cancer. 2019; 7(1):101. PMC: 6463631. DOI: 10.1186/s40425-019-0575-3. View

14.

Dulak A, Stojanov P, Peng S, Lawrence M, Fox C, Stewart C . Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013; 45(5):478-86. PMC: 3678719. DOI: 10.1038/ng.2591. View

15.

Pereira M, Ramos M, Faraj S, Dias A, Yagi O, Zilberstein B . Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer. J Surg Oncol. 2018; 117(5):829-839. DOI: 10.1002/jso.25022. View

16.

Tan I, Ivanova T, Lim K, Ong C, Deng N, Lee J . Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011; 141(2):476-85, 485.e1-11. PMC: 3152688. DOI: 10.1053/j.gastro.2011.04.042. View

17.

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

18.

Cristescu R, Lee J, Nebozhyn M, Kim K, Ting J, Wong S . Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015; 21(5):449-56. DOI: 10.1038/nm.3850. View

19.

. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017; 541(7636):169-175. PMC: 5651175. DOI: 10.1038/nature20805. View

20.

Dunne P, Alderdice M, OReilly P, Roddy A, McCorry A, Richman S . Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification. Nat Commun. 2017; 8:15657. PMC: 5460026. DOI: 10.1038/ncomms15657. View